Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology

DGK/DGPK/DGHO · 2020 · Germany

Source and licence

Authors: Tienush Rassaf, Matthias Totzeck, Johannes Backs et al.
Title: Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Journal: Clinical Research in Cardiology, 2020
DOI: 10.1007/s00392-020-01636-7
Licence: CC BY 4.0
Changes: Verbatim excerpts; formatting adapted

Full text retrieved 2026-10-27 from Europe PMC · PMC7515958

Licence statement of the original publication

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.

Open the original publication →Full text on Europe PMC

Recommendations

We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.

Abstract

The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.

Contents of the original publication

The section headings of the original.

Cardiovascular risk factors and diseases—risk assessment prior to tumour therapy
Classic risk factors
Pre-existing or concomitant cardiovascular diseases
Cardiotoxic risk induced by prior cancer treatment
Radiotherapy
Management of patients after radiotherapy
Conventional chemotherapy
Immune checkpoint inhibitor-induced myocarditis
Clinical symptoms
ECG changes
Biomarkers
Cardiac imaging
Diagnostics for suspected ICI-induced myocarditis
Supplementary diagnostics
Fundamentals of ICI-induced myocarditis therapy
Basic diagnostics and monitoring of ICI therapy patients
Targeted therapies: conventional antibodies and ‘small-molecule’ tyrosine kinase inhibitors
Multi-target tyrosine kinase inhibitors
BCR-ABL inhibitors
BRAF and MEK inhibitors
ALK inhibitors
Bruton's tyrosine kinase inhibitor
HER2 inhibitors/EGF2-dependent therapeutics
VEGFR inhibitors
New haematological therapies
Proteasome inhibitors
Histone deacetylase (HDAC) inhibitors
Immunomodulatory drugs
Chimeric antigen receptor (CAR) T-cell therapies
Childhood and adolescent cancers and their long-term sequelae
Background
Cardiovascular burden following therapy in childhood and adolescence
Transition and aspects of lifelong follow-up care
Survivorship programmes
Follow-up observation after anthracycline therapy
Radiotherapy follow-up observation
Onco-cardiology teams
Structure
Coordination of patient routing
Basic structure
Central structures (highest level of care)
Training
Selection of patients

A question about this guideline?

Medelix answers clinical questions from guidelines and studies – every statement with its source.

Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint